Conference Proceeding

A New Mechanism of Action for Drugs Used to Treat Multiple Sclerosis for Cancer

Dr. Azzam A. Maghazachi,
University of Sharjah, UAE

Dr. Azzam A. Maghazachi carried out his post doctoral research in the Kaplan Cancer Center, New York University Medical School, New York, USA. Later he started working as a Professor at University of Oslo, Norwegian capital of Oslo. He has many honours and awards; presently he is working as Professor, College of Medicine and University of Sharjah United Arab Emirates.

Purpose/Objectives: Multiple Sclerosis (MS) is an autoimmune disease, whereas cancer develops in immunodeficient individuals. Natural killer (NK) cells stand at the cross road among treatment of autoimmune diseases and immunodeficient diseases. We reported a new mechanism of action for the drug Copaxone (glatiramer acetate or GA; TEVA Inc.). NK cells isolated from patients dosed with GA lysed dendritic cells isolated from the same patients as well killing tumor target cells. Similarly, vitamin D3 or FTY720 (Gilenya; Novartis) augmented IL-2-activated NK cells lysis of tumor cells. Dimethyl fumarate (DMF; Biogen Inc.) is a new drug for treating MS patients. We have examined the effects of DMF and the metabolite monomethyl fumarate (MMF) on various activities of NK cells.

Published: 11 May 2017